OPINION: Why You Must Get Provenge Now

As you read what follows bear in mind that it is a first post from an unknown new member and it reads a bit like a press release. The information presented does seem like it might be of interest to other members of this forum but we have no way of knowing if the poster has a connection to Denderon. Just an FYI. Something here might be fishy indeed. -- PeterDA

This post is on ADVANCEDPROSTATECANCER A recent announcement stated that Dendreon’s immunotherapy Provenge (sipuleucel-T) is too expensive to be used as a treatment for advanced prostate cancer under the National Health Service in England.

In preliminary draft guidelines out this morning, the National Institute for Health and Care Excellence has rejected the drug’s use to treat men with metastatic prostate cancer before they have received chemotherapy.

It is my personal opinion, Dendreon’s economic plans for survival is directly hitched to getting the drug used in Europe where it has been approved by regulators. Given the massive economic woes Dendreon faces, the decision in the UK to not use Provenge can be described only as a major setback which greatly increases the risk that the treatment might soon no longer be available to men with advanced prostate cancer.

I’ve always felt quite frustrated and very unhappy that Dendreon has not been able to flourish so that we could be secure in always having Provenge available as a treatment modality. This guidance issued by the National Health Service is a major blow and increases the risk that Provenge might become unavailable in the very near future.

BOTTOM LINE
So what does this mean, I urge each and everyone of you who may qualify to get Provenge NOW as it might not be available in the near future. I hate being a naysayer, I hope I am 100% wrong, but if I am not I urge that you take advantage now while it is still available.

Post Edited By Moderator (PeterDisAbelard.) : 10/29/2014 3:53:19 PM (GMT-6)

This is a wake-up call to ALL the new patented drugs and therapies that offer very limited survival benefit at great cost..This is the first time a cost / benefit analysis has been used to reject an FDA approved treatment..(The FDA does not consider cost when evaluating a new drug or treatment). There was bound to be backlash when the drug companies charged outrageous prices for new drugs that offered only a marginal improvement over the old ones whose patent protection was about to expire...Single product companies like Dendreon that offer a less than spectacular product are not likely to survive unless they can drastically reduce costs..

This thread is started by an individual that may have ties to Dendreon.

JNF agreed,
In fact they would be perfect fodder for buy out if not for that debt. The fix for that is filing in the BK courts for debt relief. But the investors get the short end of that. It might encourage a post like this.

If you take the "bottom Line" paragraph, copy and paste it into Google, you will see it's a "form letter".

I find that disturbing.

It would put me more at ease if the individual would do a better job of identifying their interest here.